| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3286676 | Clinics and Research in Hepatology and Gastroenterology | 2012 | 7 Pages |
SummaryBackground and objectiveImatinib is approved worldwide for use in gastrointestinal stromal tumours (GISTs). To evaluate the efficacy and safety of two dose of imatinib treatment for patients with GISTs, a meta-analysis was performed.MethodsElectronic search of the PubMed and EMBASE, which have articles published between 1980 and February 2012, was conducted to select studies for this meta-analysis.ResultsFive articles with a total number 1861 of advanced GISTs patients were involved in this meta-analysis. There was a slight but significant 2-year PFS advantage with high-dose group (OR = 1.25, 95% CIs = 1.03–1.52, P = 0.03), but not in the 2-year OS (OR = 1.02, 95% CIs = 0.84–1.24, P = 0.87), CR (OR = 1.02, 95% CIs = 0.66–1.58, P = 0.93), and PR (OR = 1.13, 95% CIs = 0.94–1.36, P = 0.20). In safety, the high-dose group increased the incidence of above grade 3 toxicity (OR = 2.05, 95% CIs = 1.70–2.48, P < 0.00001), particular in the blood toxicity, skin disorders, nausea and so on.ConclusionsThis analysis confirms a slight 2-year PFS advantage of high-dose imatinib, but imatinib dose escalation could not lead to any other major clinical benefits, and brought more toxic effects for patients.
